$DNA Cashflow Statement | Understand Stock

$DNA

$11.27 +$1.25 (12.48%) Close

$DNA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation
Goodwill impairment
Restructuring related impairment charges
Non-cash customer consideration
Loss on equity method investments
Loss on investments
Change in fair value of notes receivable
Change in fair value of warrant liabilities
Change in fair value of contingent consideration liability
Loss on deconsolidation of subsidiaries
Impairment of long-lived assets
Deferred income tax benefit
Loss on disposal of equipment
Non-cash lease expense
Non-cash in-process research and development
Amortization of finance lease right-of-use assets
Non-cash severance and retention bonus expense associated with an acquisition
Accretion of discount on marketable securities
Other non-cash activity
Changes in operating assets and liabilities:
Accounts receivable ($357, $156 and $816 from related parties)
Prepaid expenses and other current assets
Inventory
Operating lease right-of-use assets
Other non-current assets
Accounts payable
Accrued expenses and other current liabilities
Deferred revenue, current and non-current ($(8,147), $(51,422) and $(17,018) from related parties)
Operating lease liabilities, current and non-current
Deferred rent, non-current
Other non-current liabilities

Net cash used in operating activities
Cash flows from investing activities:
Purchases of marketable debt securities
Maturities of marketable debt securities
Proceeds from sale of marketable debt securities
Purchases of property and equipment
Deconsolidation of subsidiaries - cash
Business acquisitions, net of cash acquired
Asset acquisitions, net of cash acquired
Purchases of notes receivable
Proceeds from notes receivable
Purchase of investment in equity securities
Proceeds from sales of marketable equity securities
Proceeds from sale of equipment
Other
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from reverse recapitalization, net of redemptions of $867,253 and offering costs of $108,118 (Note 3)
Proceeds from ATM offering
Payment of issuance costs related to ATM offering
Proceeds from exercise of stock options
Repurchases of common stock
Proceeds from lease financing obligation
Taxes paid related to net share settlement of equity awards
Principal payments on finance leases
Contributions from non-controlling interests
Proceeds from issuance of Series E convertible preferred stock, net of issuance costs
Proceeds from public offering, net of issuance costs
Contingent consideration payment
Payment of equity issuance costs and other
Net cash provided by (used in) financing activities

Effect of foreign exchange rates on cash and cash equivalents
Net decrease in cash, cash equivalents and restricted cash
Cash and cash equivalents, beginning of year
Restricted cash, beginning of year
Cash, cash equivalents and restricted cash, beginning of year
Cash and cash equivalents, end of year
Restricted cash, end of year
Cash, cash equivalents and restricted cash, end of year
Cash paid for interest
Cash paid for income taxes
ROU assets obtained in exchange for new operating lease liabilities upon adoption of ASC 842
ROU assets obtained in exchange for new finance lease liabilities upon adoption of ASC 842
ROU asset obtained in exchange for new operating lease liabilities
ROU asset obtained in exchange for new finance lease liabilities
Purchase of minority interest in Cooksonia
Purchases of equipment through capital leases
Lease financing obligation for build-to-suit lease
Restricted Cash
Purchases of property and equipment included in accounts payable and accrued expenses
Equity received in related parties
Convertible financial instruments received for Foundry services
Equity securities and warrants received for Foundry services
Conversion of convertible promissory notes to preferred stock
Non-cash consideration paid for the acquisition of Zymergen
Common stock issued for acquisitions
Acquisition date fair value of contingent consideration
Acquisition date fair value of warrant liabilities
Equity issuance costs in accounts payable and accrued expenses

Comments